Century Pharmaceuticals Ltd which had been manufacturing APIs since 1982 is on growth path with the introduction of new products and expansion of its existing manufacturing capacity. It has set up a US FDA approved plant and is in the process of filing ANDA soon with an American company.
Manufacture of macrolides has been the major thrust area for the company since inception. With the popularity of Roxithromycin, Azithromycin and Clarithromycin, Century has invested in increasing its capacity vertically. Several of its intermediates for these macrolides are sourced by leading multi national companies which helped in the rapid growth of the company.
As Vitamin D3 derivatives has a good potential in the local market, Century plans to introduce these products as the market for these derivatives expand. The company is in advanced stages with a technology tie-up with a Chinese company to improve its range and cost-effectiveness. Prostoglandins which are also having a great future are under development.
Century's foray into biotechnology research has resulted in a gold medal from Lockheed Martin India. It received award for innovation for the commercialisation of a recombinant protein for the treatment and cure for asthma and allergies. Century is in advanced discussions with an American company for a partnership to achieve the proof of concept for its NCE development and eventual IND filing in the US.